MY127181A - Substituted bicyclic derivatives for the treatment of abnormal cell growth - Google Patents

Substituted bicyclic derivatives for the treatment of abnormal cell growth

Info

Publication number
MY127181A
MY127181A MYPI20012895A MY127181A MY 127181 A MY127181 A MY 127181A MY PI20012895 A MYPI20012895 A MY PI20012895A MY 127181 A MY127181 A MY 127181A
Authority
MY
Malaysia
Prior art keywords
cell growth
abnormal cell
treatment
substituted bicyclic
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Morris Joel
Charles Kath John
Kumar Bhattacharya Samit
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MY127181A publication Critical patent/MY127181A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
MYPI20012895 2000-06-22 2001-06-20 Substituted bicyclic derivatives for the treatment of abnormal cell growth MY127181A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21313600P 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
MY127181A true MY127181A (en) 2006-11-30

Family

ID=22793862

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20012895 MY127181A (en) 2000-06-22 2001-06-20 Substituted bicyclic derivatives for the treatment of abnormal cell growth

Country Status (42)

Country Link
US (2) US6890924B2 (show.php)
EP (1) EP1292591B1 (show.php)
JP (1) JP4044839B2 (show.php)
KR (1) KR100545537B1 (show.php)
CN (3) CN1437594A (show.php)
AP (1) AP2001002192A0 (show.php)
AR (1) AR032353A1 (show.php)
AT (1) ATE288431T1 (show.php)
AU (1) AU2001264159A1 (show.php)
BG (1) BG107269A (show.php)
BR (1) BR0111548A (show.php)
CA (1) CA2413424C (show.php)
CZ (1) CZ20023951A3 (show.php)
DE (1) DE60108754T2 (show.php)
DK (1) DK1292591T3 (show.php)
DZ (1) DZ3407A1 (show.php)
EA (1) EA005525B1 (show.php)
EC (1) ECSP024393A (show.php)
EE (1) EE200200710A (show.php)
ES (1) ES2236240T3 (show.php)
GE (1) GEP20063831B (show.php)
HR (1) HRP20021005A2 (show.php)
HU (1) HUP0301120A2 (show.php)
IL (1) IL152985A0 (show.php)
IS (1) IS6616A (show.php)
MA (1) MA26914A1 (show.php)
MX (1) MXPA02012870A (show.php)
MY (1) MY127181A (show.php)
NO (1) NO20026166L (show.php)
NZ (1) NZ522568A (show.php)
OA (1) OA12291A (show.php)
PA (1) PA8520301A1 (show.php)
PE (1) PE20020257A1 (show.php)
PL (1) PL359557A1 (show.php)
PT (1) PT1292591E (show.php)
SK (1) SK17102002A3 (show.php)
SV (1) SV2002000504A (show.php)
TN (1) TNSN01091A1 (show.php)
UA (1) UA73990C2 (show.php)
WO (1) WO2001098277A2 (show.php)
YU (1) YU95102A (show.php)
ZA (1) ZA200210231B (show.php)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
DE69905264T2 (de) * 1998-10-01 2003-12-11 Astrazeneca Ab, Soedertaelje Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
SK17102002A3 (sk) * 2000-06-22 2004-04-06 Pfizer Products Inc. Substituované bicyklické deriváty na liečbu abnormálneho bunkového rastu
CN1264824C (zh) * 2001-02-21 2006-07-19 三菱制药株式会社 喹唑啉衍生物
US20030144308A1 (en) * 2001-09-24 2003-07-31 Bauer Paul H. Fructose 1,6-bisphosphatase inhibitors
ES2295409T3 (es) * 2001-11-30 2008-04-16 Osi Pharmaceuticals, Inc. Procedimiento para la preparacion de derivados biciclicos sustituidos para el tratamiento de crecimiento anormal de celulas.
HRP20040529A2 (en) * 2001-12-12 2004-10-31 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
MXPA04005678A (es) * 2001-12-12 2004-12-06 Pfizer Prod Inc Formas de sal de e-2 -metoxi -n- (3- (4- (3-metil -piridin-3- iloxil ) fenilamino) quinazolin -6-il) alil) alil) acetamida, su preparacion y su uso contra el cancer.
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
EP1567506A4 (en) 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
KR20050085749A (ko) * 2002-12-18 2005-08-29 화이자 프로덕츠 인크. 비정상적 세포 성장의 치료를 위한 4-아닐리노 퀴나졸린유도체
AU2003283743A1 (en) * 2002-12-19 2004-07-14 Pfizer Products Inc. Complexes of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
RS20050652A (sr) * 2003-04-09 2007-11-15 Pfizer Products Inc., Postupak za izradu derivata n- (((piridiniloksi)-fenilamino) kvinazolinil)-alil)acetamida i izvedenih jedinjenja kao i međuproizvodi ovih postupaka i postupci za izradu ovih međuproizvoda
MXPA05012839A (es) * 2003-05-27 2006-05-17 Pfizer Prod Inc Quinazolinas y pirido[3,4-d] pirimidinas como inhibidores de receptores tirosina quinasa.
US7618975B2 (en) * 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1822853A (zh) * 2003-07-15 2006-08-23 加拿大国家研究委员会 用于治疗特征在于过度增殖皮肤细胞的疾病的人类甲状旁腺激素环状类似物
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN103772373B (zh) * 2003-08-14 2017-06-09 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
JP2007502807A (ja) * 2003-08-18 2007-02-15 ファイザー・プロダクツ・インク Ｅｒｂｂ２抗がん剤の投与スケジュール
SI1667991T1 (sl) 2003-09-16 2008-10-31 Astrazeneca Ab Kinazolinski derivati kot inhibitorji tirozin kinaze
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
PL2392565T3 (pl) 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
WO2005044302A1 (en) * 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
EP2322215A3 (en) 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
JPWO2006025490A1 (ja) * 2004-09-01 2008-05-08 田辺三菱製薬株式会社 分子シャペロン機能調節剤
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
KR100990027B1 (ko) 2005-04-26 2010-10-26 화이자 인코포레이티드 Ｐ-카드헤린 항체
WO2006129168A2 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Bicyclic derivatives for the treatment of abnormal cell growth
CA2610661A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
PT1933871E (pt) 2005-09-07 2013-07-17 Pfizer Anticorpos monoclonais humanos para cinase-1 do tipo receptor de activina
ES2364901T3 (es) 2005-11-15 2011-09-16 Array Biopharma, Inc. Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
UA91129C2 (ru) 2006-05-09 2010-06-25 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
WO2008002039A1 (en) * 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
SG174774A1 (en) * 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
JP2010502743A (ja) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2103620A1 (en) 2006-12-12 2009-09-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
JP5926487B2 (ja) 2007-04-13 2016-05-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ＥｒｂＢ療法に耐性である癌を治療するための方法
BRPI0907916A2 (pt) 2008-02-07 2015-07-28 Boehringer Ingelheim Int Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
PE20091580A1 (es) 2008-03-12 2009-11-05 Takeda Pharmaceutical Compuesto heterociclico fusionado
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
TWI511956B (zh) 2009-01-16 2015-12-11 Exelixis Inc 製備ｎ-（４-｛〔６，７-雙（甲氧基）喹啉-４-基〕氧基｝苯基）-ｎ’-（４-氟苯基）環丙烷-１，１-二甲醯胺之方法
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
EP2630134B9 (en) 2010-10-20 2018-04-18 Pfizer Inc Pyridine-2- derivatives as smoothened receptor modulators
BR112014006840A2 (pt) 2011-09-22 2017-04-04 Pfizer derivados de pirrolopirimidina e purina
CN102872018B (zh) * 2012-10-23 2015-07-15 广州市恒诺康医药科技有限公司 酪氨酸激酶不可逆抑制剂及其制备方法和用途
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
ES2759434T3 (es) 2014-04-30 2020-05-11 Pfizer Derivados de diheterociclo unidos a cicloalquilo
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
EP3424928A4 (en) 2016-03-01 2019-10-09 Shanghai Pharmaceuticals Holding Co., Ltd. NITROGENIC HETEROCYCLIC COMPOUND, MANUFACTURING METHOD, INTERMEDIATE PRODUCT, COMPOSITION AND USE
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
LT3853220T (lt) 2018-09-18 2024-03-12 F. Hoffmann-La Roche Ag Chinazolino dariniai kaip antinavikiniai preparatai
JP2025509995A (ja) * 2022-03-28 2025-04-11 江蘇恒瑞医薬股▲ふん▼有限公司 含窒素複素環系化合物、その調製方法及びその医薬的使用
WO2025067396A1 (zh) * 2023-09-27 2025-04-03 江苏恒瑞医药股份有限公司 一种喹唑啉衍生物的可药用盐、其结晶形式及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (show.php) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ES2241324T3 (es) 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
SK17102002A3 (sk) * 2000-06-22 2004-04-06 Pfizer Products Inc. Substituované bicyklické deriváty na liečbu abnormálneho bunkového rastu

Also Published As

Publication number Publication date
EP1292591B1 (en) 2005-02-02
NO20026166D0 (no) 2002-12-20
EA005525B1 (ru) 2005-04-28
JP4044839B2 (ja) 2008-02-06
US6890924B2 (en) 2005-05-10
IS6616A (is) 2002-11-14
GEP20063831B (en) 2006-05-25
CZ20023951A3 (cs) 2004-01-14
SV2002000504A (es) 2002-10-24
MXPA02012870A (es) 2003-05-14
EE200200710A (et) 2004-06-15
UA73990C2 (en) 2005-10-17
ZA200210231B (en) 2004-02-12
CN1437594A (zh) 2003-08-20
DE60108754D1 (de) 2005-03-10
YU95102A (sh) 2005-11-28
MA26914A1 (fr) 2004-12-20
PE20020257A1 (es) 2002-04-08
AR032353A1 (es) 2003-11-05
KR100545537B1 (ko) 2006-01-25
DE60108754T2 (de) 2005-06-23
WO2001098277A3 (en) 2002-06-13
TNSN01091A1 (fr) 2005-11-10
PA8520301A1 (es) 2003-06-30
US20050159435A1 (en) 2005-07-21
ECSP024393A (es) 2003-02-06
KR20030016303A (ko) 2003-02-26
CA2413424C (en) 2007-10-02
HK1069576A1 (en) 2005-05-27
AU2001264159A1 (en) 2002-01-02
HRP20021005A2 (en) 2004-02-29
AP2001002192A0 (en) 2002-12-21
HUP0301120A2 (hu) 2003-08-28
JP2004501139A (ja) 2004-01-15
CA2413424A1 (en) 2001-12-27
IL152985A0 (en) 2003-06-24
PT1292591E (pt) 2005-06-30
NZ522568A (en) 2004-12-24
BR0111548A (pt) 2003-05-06
EP1292591A2 (en) 2003-03-19
CN101348467A (zh) 2009-01-21
WO2001098277A2 (en) 2001-12-27
DZ3407A1 (show.php) 2001-12-27
CN1576275A (zh) 2005-02-09
SK17102002A3 (sk) 2004-04-06
OA12291A (en) 2004-03-18
ATE288431T1 (de) 2005-02-15
US20020169165A1 (en) 2002-11-14
PL359557A1 (en) 2004-08-23
ES2236240T3 (es) 2005-07-16
DK1292591T3 (da) 2005-05-30
NO20026166L (no) 2002-12-20
EA200201277A1 (ru) 2003-06-26
BG107269A (bg) 2003-06-30
CN1330640C (zh) 2007-08-08
US7332493B2 (en) 2008-02-19

Similar Documents

Publication Publication Date Title
MY127181A (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
MY139357A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
ATE260263T1 (de) Heteroaromatische bizyklische verbindungen mit antikrebswirkung
DE69923849D1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
BG104998A (en) Isothiazole derivatives useful as anticancer agents
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
AP2001002079A0 (en) Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents.
MX9707980A (es) Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos.
MY136270A (en) Processes and intermediates for preparing anti-cancer compounds
TW200630361A (en) Integrin antagonists useful as anticancer agents
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
TNSN02096A1 (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
DE69734678D1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
WO2006129168A3 (en) Bicyclic derivatives for the treatment of abnormal cell growth
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
AP2001002154A0 (en) Hygromycin a derivatives (changed by the ISA to read hygromycin a derivatives as antibacterial agents.
MXPA02011966A (es) Derivados de higromicina a para el el tratamiento de infecciones bacterianas y por protozoarios.
UY26785A1 (es) Derivados bicíclicos sustituidos para el tratamiento del crecimiento celular anormal